PREVALENCE OF DRUG RESISTANCE TO FIRST LINE DRUGS AMONG TUBERCULOSIS PATIENTS IN ASTANA

• Published in: Tuberkulëz i bolezni lëgkikh Vol. 96; no. 8; pp. 50 - 54
• Main Authors: RАKISHEVА, ZH. K., BАLАSАNYANTS, G. S., АKISHEVА, А. S., TSEPKE, А. B., SOLOVIEVА, N. S.
• Format: Journal Article
• Language: English; Russian
• Published: New Terra Publishing House 01.09.2018
• Subjects: мультирезистентность; полирезистентность; противотуберкулезные препараты первого ряда; туберкулез
• ISSN: 2075-1230; 2542-1506
• DOI: 10.21292/2075-1230-2018-96-8-50-54

The objective of the study: to study the prevalence of resistance to first line drugs among tuberculosis patients in Astana (Kazakhstan Republic).Subjects and methods. Data on resistance to first line drugs according to the WHO classification were analyzed, they included sputum test results of 449 patients with bacillary excretion who received in-patient treatment in TB Dispensary in Astana in 2017. Bactec and Hain test were used for drug susceptibility testing.Results. The study showed that among new tuberculosis patients and relapses, resistance to isoniazid (H) dominated and made 87.4% (76 out of 87) and 91.1% (41 out of 45) of cases respectively. Resistance to H was registered more often versus resistance to streptomycin. H-resistant strains were detected confidently more often than rifampicin resistance: 76/226 (33.6%) versus 18/226 (8.0%) among all new cases (p < 0.01) and 41/133 (26.1%) versus 5/133 (3.2%) of all relapses (p < 0.01).Among new cases with drug resistant tuberculosis, the frequency of rifampicin resistant strains was compatible with the frequency of resistance to ethambutol. It was found out that the frequency of resistance to pyrazinamide was low.The performed analysis confirmed that when prescribing treatment to tuberculosis patients it was necessary to investigate the resistance to first line drugs with much detail.